CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab.

ABSTRACT:

Introduction

Growing evidence suggests a role for neuroinflammation in Alzheimer's disease (AD). We investigated complement pathway activity in AD patient cerebrospinal fluid (CSF) and evaluated its modulation by the anti-tau antibody semorinemab.

Methods

Immunoassays were applied to measure CSF complement proteins C4, factor B (FB), C3 and their cleavage fragments C4a, C3a, and factor Bb (Bb) in AD patients and a separate cognitively unimpaired (CU) cohort.

Results

All measured CSF complement proteins were increased in AD versus CU subjects, with C4a displaying the most robust increase. Finally, semorinemab did not have a significant pharmacodynamic effect on CSF complement proteins.

Discussion

Elevated levels of CSF C4a, C4, C3a, C3, Bb, and FB are consistent

SUBMITTER: Sandoval C 

PROVIDER: S-EPMC11567840 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature